Bullous pemphigoid treated with dexamethasone-cyclophosphamide pulse therapy

Ramji Gupta

Abstract


Objective To induce  permanent remission in bullous pemphigoid patients.

 

Methods 5 patients of bullous pemphigoid treated with dexamethasone-cyclophosphamide pulse (DCP) therapy are being reported. Diagnosis was confirmed by histopathology and immunofluorescence test. Each pulse comprised of dexamethasone 100 mg dissolved in 500 ml of glucose and transfused intravenously over 1-1.5 hours on three consecutive days. On 2nd day cyclophosphamide 500 mg was transfused through the same drip. It was repeated every 28 days. In between oral cyclophosphamide 50mg daily was given. The whole treatment was divided into 4 phases: phase I, till all the lesions cleared; phase II, no lesions but still DCP was given for 9 months; phase III DCP withdrawn, only oral cyclophosphamide 50mg daily was given for 9 months; and in phase IV, all the treatment was withdrawn and patients are followed-up as much as possible. Period of remission was noted.

 

Results Out of five, three patients entered into remission up to 7.5 years after stoppage of all treatment. Remaining two are in remission for one to two years.

 

Conclusion Dexamethasone-cyclophosphamide pulse therapy is able to induce permanent remission in bullous pemphigoid.

 


Keywords


Bullous pemphigoid, dexamethasone-cyclophosphamide pulse therapy, DCP

Full Text:

PDF

References


Pasricha JS, Gupta Ramji. Pulse therapy with dexamethasone in Reiter’s disease (A case port). Indian J dermatol Venereol leprol 1982; 48: 358-61

Pasricha JS, Gupta Ramji. Pulse therapy with dexamethasone cyclophosphamide in pemphigus. Indian J dermatol Venereol leprol 1984; 50:199-203

Gupta Ramji. Prolonged remission of pemphigus induced by dexamethasone cyclophosphamide pulse therapy. Indian J dermatol Venereol leprol 2007; 73: 121-3

Gupta Ramji, Gupta Sachi, Gupta Anil. Efficiency and safety of dexamethasone cyclophosphamide pulse therapy in the treatment of pemphigus –An open randomized controlled study. Apollo medicine 2015; 243-7

Gupta Ramji, Gupta Sarthak, Khera Vikas. Systemic lupus erythematosis response to dexamethasone –cyclophosphamide pulse therapy. J Dermatology Treatment 2008; 20:55-8

PasrichaJ S,Ramam M, Shah S. Reversal of systemic sclerosis with dexamethasone pulse therapy. Indian J dermatol Venereol leprol 1990; 56:40-2

Gupta Ramji. Systemic sclerosis treated with dexamethasone pulse therapy. Indian J dermatol Venereol leprol 2003;69:191-2

Pasricha JS, Reddy R, Nanda Kishore Th, et al. Pyoderma gangrenosum treated with dexamethasone pulse therapy. Indian J dermatol Venereol and leprol 1991; 57:225-8

Gupta Ramji, Gupta Sarthak. Dexamethasone cyclophosphamide pulse therapy in lichen amyloidosus : A case report. J Dermatology Treatment 2007; 18:249-51

Gutpa Ramji, Gupta Sachi. Peyronie’s disease treated with oral weekly dexamethasone and continuous low dose cyclophosphamide. Indian J dermatol Venereol and leprol 2014;59 : 317

Gupta Ramji. Treatment of prurigo nodularis with dexamethasone- cyclophosphamide pulse therapy. Indian J dermatol Venereol leprol 2016;82: 239-41

Gupta Ramji. Prolonged remission of rheumatoid arthritis with dexamethasone cyclophosphamide pulse therapy: A case series. Indian J rheumatol 2014; 98-100

Khandpur S, Verma P. Bullous pemphigoid. Indian J dermatol Venereol leprol 2011 ; 77:450-455

Appelhans M, Bonsman S, Orge C, et al. Dexamethasone cyclophosphamide

pulse therapy in bullous auto-immune dermatology . Hautarzt 1993;44:143-7


Refbacks

  • There are currently no refbacks.


ISSN: 1560-9014